ANI Bought a Second Rare Disease Leg — and the Market Only Priced the First One
A $560M ultra-rare deal and a second Cortrophin guidance cut landed in the same press release; the tape spent 90 days deciding which one mattered
ANIP · Earnings Call · 2026-11-05
Two Stories, One Morning
ANI Pharmaceuticals put up the best top line in its history in Q3 2026 and still walked into a stock that is down roughly 16% over 90 trading days and about 19% off its July high. Revenue came in at $290.8M (+28% y/y), adjusted EBITDA $82.3M (+40%), and operating cash flow set a record at $83.8M for the quarter. Total revenue has now grown for eleven consecutive years, and the operating margin of 15.2% is up 8.6pp year-over-year, a genuine step-change from the loss-making 2022-2023 stretch. Operating margin history.
None of that is what the tape argued with. Two things happened in the same release, and only one of them got marked.
The Bottleneck Nobody Modeled
Cortrophin Gel guidance was cut to $480-500M from $520-540M. This is the second consecutive trim: in August the range moved from $540-575M down to $520-540M, with management framing that revision as largely a first-half accounting exercise rather than a change in outlook. At the time, the CEO was explicit that the back half was intact and that the pipeline of demand indicators — breadth of prescribing, depth of prescribing, reps with multiple new cases — was running ahead of plan. The August Q&A made the point sharply when David Amsellem of Piper Sandler asked directly about lag from script to fill.
“So there is no lag or any new headwind that we're facing on that front.” — Nikhil Lalwani, President and Chief Executive Officer · 2026-08-07
We do not see any additional headwinds in the back half of the year. And our, very importantly, our expectations for the back half of the year are largely intact with what we had originally anticipated at the start of the year.
Three months later, the lag and the headwind are precisely the diagnosis. Christopher Mutz described the mechanism without dressing it up:
Simply put, the significant increase in volumes created a bottleneck in our network. This led to slower reimbursement processing in gout cases as well as cases in our existing specialties.
The tell is in the keywords. specialty pharmacy went from a routine mention to the single highest-momentum theme in this company's vocabulary this quarter, joined by the operational machinery around it — the enrollment to fulfillment handoff and the network capacity behind it. Meanwhile leading indicators — the demand metrics management leaned on heavily in August — faded, conceptually and in rank terms, this quarter. That is the right instinct: the leading indicators were right, and they were also the problem. The gout expansion generated so many new case initiations (85% more in the five months post-expansion than the five before) that the fulfillment rails flexed.
The CEO's answer to Vamil Divan's question was refreshingly direct: had conversion behaved, Q3 would have hit plan.
“If we had not had the revenue conversion you know, dynamics that we have had, would we have achieved the Q3 guidance? Absolutely.” — Nikhil Lalwani, President and Chief Executive Officer · 2026-11-05
And the framing on the fix is that this is a timing problem, not a demand problem — “the conversion of patients to therapy, it is a question of when, not if.” — Nikhil Lalwani, President and Chief Executive Officer · 2026-11-05 Note what he also said plainly: gout is not a bigger share of the pie than originally planned. This is not a mix failure being spun as an execution hiccup.
A Second Rare Disease Leg
Slipped into the same morning: an all-cash offer of $560M in equity consideration for Aegidus Therapeutics, an enterprise value near $434M net of a $95M priority review voucher sale, funded with roughly $300M of cash and up to $300M of new JPMorgan bridge debt. The asset is emcetate, the first and only approved therapy for MCT8 deficiency — an X-linked disease of peripheral thyroid hormone toxicity with an estimated incidence of 1 in 70,000 males, more than 1,000 prevalent US patients, a median life expectancy of about 35 years, and roughly 30% mortality in childhood.
This is genuinely new vocabulary for ANI: Aegidus, emcetate, and Ultra rare disease all appear at the top of the company's keyword trajectory for the first time. It is also a different commercial muscle than Cortrophin: a tablet, taken daily, dosed by weight, dispensable through a G-tube, and priced at roughly $950,000 annualized WAC. Management pegs peak sales potential above $300M in the approved indication alone, and the launch starts with a real running start — about 60 US patients already on an EAP program and 300 globally across managed access, out of 100+ genetically confirmed US patients concentrated at 17 sites.
The strategic logic is coherent, and it is the logic ANI has been telegraphing for four quarters in every BD answer: commercial-stage, durable IP into mid-2045, leverage the existing market access and patient-support rails. What is less flattering is the near-term mathematics. Management concedes dilution to adjusted EPS and EBITDA in year one, with pro forma net leverage moving from 0.7x to about 2.7x. The company spent the first nine months building the war chest — Effective net cash flipped from a $23M net debt position to $59M of net cash — and is now deploying it in one stroke.
What Went Quiet
Two silences are worth naming. First, ILUVIEN: revenue grew 34% to $22.3M and guidance was raised to $80-85M, yet the retina franchise has drifted out of the narrative. Its defining keyword, NIU PS, is losing momentum after several quarters of promise around the SYNCHRONICITY data. Second, the buyback. The board authorized $100M in May, ANI repurchased $20M at an average of about $72.54 — and then essentially stopped: share repurchases collapsed to under $1M in the latest quarter. The CEO called the buyback a reflection of confidence in the future; the capital allocation that followed says the future was Aegidus.
Underneath, the quiet engine remains generics at $104.5M (+11%) with 16 launches year-to-date and a number-two position in CGT filings, plus Harmony royalty income of $11.5M. Gross margin of 61.8% improved 260bps on mix. And R&D remains deliberately modest — R&D as a share of revenue.
The Verdict
There is no market-wide wave here. Nothing in the broader keyword tape or the global price movers touches ACTH, MCT8, or ultra-rare endocrinology — this is a purely idiosyncratic story, which makes the evidence quality the whole game. On that measure the call is credible but not yet proven: the demand data are strong and independently corroborated by prescriber counts, the bottleneck explanation is mechanically specific rather than hand-wavy, and the deal adds a durable, high-price, low-competition asset. Against that sits a two-quarter pattern of guidance erosion and a management team that told investors in August there was no conversion lag. The stock's 90-day drawdown is the market charging for that gap — and the burden now is to show a Q4 where specialty pharmacy capacity, not demand, is the binding constraint it claims to have fixed.